Evaluation of Navigated Laser Photocoagulation (Navilas 577+)‎ for the Treatment of Refractory Diabetic Macular Edema

Abstract EN

Purpose.

To evaluate navigated laser photocoagulation for the treatment of refractory diabetic macular edema (DME).

Methods.

Retrospective study of 25 eyes (21 patients) treated with Navilas 577+ focal laser system.

Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (OCT) parameters were measured at baseline, 1, 3, and 6 months, and final visit.

Results.

The mean follow-up period was 12.8 ± 2.4 (7–16 months).

All subjects had history of previous treatment which was injection of triamcinolone acetonide or antivascular endothelial growth factor (VEGF) agents.

The navigated laser photocoagulation was delivered to the microaneurysms on indocyanine green angiography (ICGA) in 21 of 25 eyes (84%), fluorescein angiography (FA) guided in 3 eyes, and OCT angiography guided in 1 eye.

After initial navigated laser treatment, 16 of 25 eyes (64%) were needed additional navigated laser photocoagulation, injection of triamcinolone acetonide, and/or injection of VEGF agents.

Although median BCVA remained stable, the central retinal thickness and macular volume were significantly decreased over 6 months (p<0.05).

All patients were treated without complications.

Conclusions.

Focal photocoagulation using Navilas 577+ showed to be effective in treating DME with improvement in macular edema on OCT over 6 months.

Navilas 577+ was beneficial to perform navigated laser photocoagulation based on three modalities (ICGA, FA, and OCT angiography).